(Q33180838)

English

Combination raltitrexed (Tomudex(R))-oxaliplatin: a step forward in the struggle against mesothelioma? The Institut Gustave Roussy experience with chemotherapy and chemo-immunotherapy in mesothelioma

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

23 July 2017

0 references

Combination raltitrexed (Tomudex(R))-oxaliplatin: a step forward in the struggle against mesothelioma? The Institut Gustave Roussy experience with chemotherapy and chemo-immunotherapy in mesothelioma (English)

1 reference

Europe PubMed Central

PubMed publication ID

23 July 2017

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Fizazi K

1

1 reference

Europe PubMed Central

PubMed publication ID

23 July 2017

Caliandro R

2

1 reference

Europe PubMed Central

PubMed publication ID

23 July 2017

Soulié P

3

1 reference

Europe PubMed Central

PubMed publication ID

23 July 2017

Fandi A

4

1 reference

Europe PubMed Central

PubMed publication ID

23 July 2017

Daniel C

5

1 reference

Europe PubMed Central

PubMed publication ID

23 July 2017

Bedin A

6

1 reference

Europe PubMed Central

PubMed publication ID

23 July 2017

Doubre H

7

1 reference

Europe PubMed Central

PubMed publication ID

23 July 2017

Viala J

8

1 reference

Europe PubMed Central

PubMed publication ID

23 July 2017

Rodier J

9

1 reference

Europe PubMed Central

PubMed publication ID

23 July 2017

Trandafir L

10

1 reference

Europe PubMed Central

PubMed publication ID

23 July 2017

Le Chevalier T

11

1 reference

Europe PubMed Central

PubMed publication ID

23 July 2017

Cvitkovic E

12

1 reference

Europe PubMed Central

PubMed publication ID

23 July 2017

Armand J

13

1 reference

Europe PubMed Central

PubMed publication ID

23 July 2017

Ruffié P

14

1 reference

Europe PubMed Central

PubMed publication ID

23 July 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 August 2000

1 reference

Europe PubMed Central

PubMed publication ID

23 July 2017

European Journal of Cancer

1 reference

Europe PubMed Central

PubMed publication ID

23 July 2017

36

1 reference

Europe PubMed Central

PubMed publication ID

23 July 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

23 July 2017

1514-1521

1 reference

Europe PubMed Central

PubMed publication ID

23 July 2017

Malignant pleural mesothelioma: a disease unaffected by current therapeutic maneuvers

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900139-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900139-8

7 January 2021

based on heuristic

inferred from DOI database lookup

A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900139-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Continuing increase in mesothelioma mortality in Britain.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900139-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900139-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapy in malignant pleural mesothelioma. A review.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900139-8

7 January 2021

based on heuristic

inferred from DOI database lookup

A review of chemotherapy trials for malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900139-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900139-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Combined systemic chemoimmunotherapy in advanced diffuse malignant mesothelioma. Report of a phase I-II study of weekly cisplatin/interferon alfa-2a

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900139-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Higher doses of alpha-interferon do not increase the activity of the weekly cisplatin-interferon combination in advanced malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900139-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I, dose-finding, and pharmacokinetic study of raltitrexed combined with oxaliplatin in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900139-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Is òne cycle every three or four weeks' obsolete? A critical review of dose-dense chemotherapy in solid neoplasms

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900139-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Weekly high-dose cisplatin in malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900139-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900139-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900139-8

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900139-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Potential for cytokine therapy of malignant mesothelioma.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900139-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of recombinant interferon-beta ser on primary human tumor colony-forming units

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900139-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of interferon-alpha 2a on malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900139-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Recombinant interferon alpha-2b in the treatment of diffuse malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900139-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II evaluation of recombinant interferon-beta (IFN-beta ser) in patients with diffuse mesothelioma: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900139-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon alpha and doxorubicin in malignant mesothelioma: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900139-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of malignant pleural mesothelioma with cisplatin, mitomycin C and alpha interferon.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900139-8

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II trial investigating primary immunochemotherapy for malignant pleural mesothelioma and the feasibility of adjuvant immunochemotherapy after maximal cytoreduction

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900139-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Cisplatin, mitomycin, and interferon-alpha2a combination chemoimmunotherapy in the treatment of diffuse malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900139-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Folate-based thymidylate synthase inhibitors as anticancer drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900139-8

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900139-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Trimetrexate in malignant mesothelioma: A Cancer and Leukemia Group B Phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900139-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Dihydro-5-azacytidine in malignant mesothelioma. A phase II trial demonstrating activity accompanied by cardiac toxicity. Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900139-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900139-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900139-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900139-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Oxaliplatin: a review of preclinical and clinical studies.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900139-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0959-8049(00)00139-8

1 reference

Europe PubMed Central

PubMed publication ID

23 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

23 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33180838&oldid=1964332141"